Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status approved; investigational
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII 6804DJ8Z9U
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Breast cancer stage IV21.05.01.010; 16.10.01.0030.000112%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.0120.000951%
Bundle branch block left02.03.01.0070.000392%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.007880%Not Available
Cachexia14.03.02.001; 16.32.03.011; 08.01.01.0090.000168%Not Available
Cardiac arrest02.03.04.0010.003358%
Cardiac failure02.05.01.001--
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.001735%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.000728%Not Available
Cardiomyopathy02.04.01.0010.001086%Not Available
Cataract06.06.01.001--
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Cerebellar ataxia08.01.02.006; 17.02.02.0130.000224%Not Available
Cerebellar infarction24.04.06.007; 17.08.01.0130.000112%Not Available
Cerebral atrophy17.11.01.0010.000112%Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.0050.000392%
Cerebral venous thrombosis24.01.04.005; 17.08.03.0020.000336%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Change of bowel habit07.02.03.002--Not Available
Cheilitis23.03.03.025; 07.05.01.0010.000358%
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.002843%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.007980%Not Available
Chills15.05.03.016; 08.01.09.001--
Cholangiocarcinoma16.07.01.002; 09.04.02.0090.000112%Not Available
Cholangitis09.02.01.0020.000616%Not Available
Cholecystitis09.03.01.0010.001242%
Cholecystitis acute09.03.01.0030.000224%Not Available
Cholestasis09.01.01.0010.000616%Not Available
Chromaturia20.02.01.0020.001041%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene